Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center

A panel of experts from the Moffit Cancer Center share updates in the multiple myeloma treatment landscape, highlighting recent clinical data and aspects of their own experience.

EP. 1: Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center

December 14th 2022

Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.

EP. 2: Transplant-Eligible NDMM: Overview of Available Induction Therapies

January 20th 2023

Experts from the Moffit Cancer Center share insight on induction therapy strategies and optimization for patients with transplant-eligible newly diagnosed multiple myeloma.

EP. 3: Selection of Induction Therapy in Patients With Transplant-Eligible NDMM

January 20th 2023

Shared insight from experts in multiple myeloma on the real-world utilization of induction therapy and transplant for patients with newly diagnosed disease.

EP. 4: Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

January 25th 2023

Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.

EP. 5: Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM

January 25th 2023

Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.

EP. 6: Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients

February 1st 2023

Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.

EP. 7: Treatment Duration in Patients With Transplant-Ineligible NDMM

February 1st 2023

Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.